These findings highlight Hi-C’s ability to detect complex genomic events that influence prognosis and therapeutic decision-making, such as TP53 loss, which is associated with poor outcomes in DLBCL, and KMT2A amplification, which may indicate eligibility for targeted therapies. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.